Six-month comparative outcomes of aflibercept and faricimab in treatment-naïve macular edema secondary to branch retinal vein occlusion.

IF 1.9 3区 医学 Q2 OPHTHALMOLOGY
Taiichi Hikichi, Haruka Kurabe, Amane Notoya, Yuuna Oguro, Misaki Hirano, Yumeka Doi
{"title":"Six-month comparative outcomes of aflibercept and faricimab in treatment-naïve macular edema secondary to branch retinal vein occlusion.","authors":"Taiichi Hikichi, Haruka Kurabe, Amane Notoya, Yuuna Oguro, Misaki Hirano, Yumeka Doi","doi":"10.1007/s10384-025-01254-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To compare the 6-month outcomes of aflibercept and faricimab in treatment-naïve macular edema secondary to branch retinal vein occlusion (BRVOME).</p><p><strong>Study design: </strong>Retrospective observational study.</p><p><strong>Methods: </strong>The charts of consecutive treatment-naïve eyes with BRVOME treated with intravitreal injection therapy between December 2023 and August 2024 at Hikichi Eye Clinic (Sapporo, Japan) were reviewed; all eyes treated between December 2023 and April 2024 were administrated with aflibercept and all eyes treated between May 2024 and August 2024 were administrated with faricimab. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were assessed at baseline, 1, 3, and 6 months. Injection frequency and safety were also evaluated.</p><p><strong>Results: </strong>Fifty-four eyes (29 aflibercept, 25 faricimab) were included. Both groups showed significant improvement in BCVA (from 0.39 ± 0.29 to 0.09 ± 0.23) and CFT (from 617 ± 132 to 201 ± 68 µm) over 6 months (p < 0.001). The mean number of injections was significantly lower in the faricimab group (1.96 ± 0.68) than the aflibercept group (2.45 ± 0.87; p = 0.024). No serious adverse events were reported.</p><p><strong>Conclusion: </strong>Faricimab achieved similar visual and anatomical outcomes to aflibercept while requiring fewer injections, suggesting a potential advantage in reducing treatment burden.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10384-025-01254-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To compare the 6-month outcomes of aflibercept and faricimab in treatment-naïve macular edema secondary to branch retinal vein occlusion (BRVOME).

Study design: Retrospective observational study.

Methods: The charts of consecutive treatment-naïve eyes with BRVOME treated with intravitreal injection therapy between December 2023 and August 2024 at Hikichi Eye Clinic (Sapporo, Japan) were reviewed; all eyes treated between December 2023 and April 2024 were administrated with aflibercept and all eyes treated between May 2024 and August 2024 were administrated with faricimab. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were assessed at baseline, 1, 3, and 6 months. Injection frequency and safety were also evaluated.

Results: Fifty-four eyes (29 aflibercept, 25 faricimab) were included. Both groups showed significant improvement in BCVA (from 0.39 ± 0.29 to 0.09 ± 0.23) and CFT (from 617 ± 132 to 201 ± 68 µm) over 6 months (p < 0.001). The mean number of injections was significantly lower in the faricimab group (1.96 ± 0.68) than the aflibercept group (2.45 ± 0.87; p = 0.024). No serious adverse events were reported.

Conclusion: Faricimab achieved similar visual and anatomical outcomes to aflibercept while requiring fewer injections, suggesting a potential advantage in reducing treatment burden.

阿非利西普和法利西单抗治疗视网膜分支静脉闭塞treatment-naïve黄斑水肿的六个月比较结果。
目的:比较阿非利西贝和法利昔单抗治疗视网膜分支静脉闭塞(BRVOME) treatment-naïve黄斑水肿的6个月疗效。研究设计:回顾性观察性研究。方法:回顾2023年12月至2024年8月在日本札幌市市市眼科诊所(Hikichi Eye Clinic)连续treatment-naïve眼接受BRVOME玻璃体注射治疗的病例;所有于2023年12月至2024年4月治疗的眼均给予阿夫利西普,所有于2024年5月至2024年8月治疗的眼均给予法利昔单抗。在基线、1、3和6个月时评估最佳矫正视力(BCVA)和中央中央凹厚度(CFT)。并对注射频率和安全性进行了评价。结果:54只眼(29只afliberept, 25只faricimab)。两组在6个月内BCVA(从0.39±0.29到0.09±0.23)和CFT(从617±132到201±68µm)均有显著改善(p < 0.001)。法利西单抗组平均注射次数(1.96±0.68次)显著低于阿布西普组(2.45±0.87次);P = 0.024)。无严重不良事件报告。结论:Faricimab与aflibercept具有相似的视觉和解剖效果,同时需要更少的注射,这表明Faricimab在减轻治疗负担方面具有潜在优势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.80
自引率
8.30%
发文量
65
审稿时长
6-12 weeks
期刊介绍: The Japanese Journal of Ophthalmology (JJO) was inaugurated in 1957 as a quarterly journal published in English by the Ophthalmology Department of the University of Tokyo, with the aim of disseminating the achievements of Japanese ophthalmologists worldwide. JJO remains the only Japanese ophthalmology journal published in English. In 1997, the Japanese Ophthalmological Society assumed the responsibility for publishing the Japanese Journal of Ophthalmology as its official English-language publication. Currently the journal is published bimonthly and accepts papers from authors worldwide. JJO has become an international interdisciplinary forum for the publication of basic science and clinical research papers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信